Document Detail

Intervention in ischaemia. Reperfusion syndrome. Rationale for trimetazidine.
MedLine Citation:
PMID:  7818939     Owner:  NLM     Status:  MEDLINE    
Although early reperfusion of cardiac tissue is now considered to be the only intervention capable of restoring the various cellular functions altered by ischaemia and preventing progression towards necrosis of myocardial cells, reperfusion is frequently accompanied by various manifestations grouped under the heading of reperfusion syndrome or reperfusion injury. Functional recovery is therefore not immediate, but usually appears after a certain delay following a period of contractile dysfunction (myocardial stunning) lasting for several hours or even days after the start of reperfusion. Characteristics reperfusion-induced arrhythmias are also observed. The cellular mechanisms underlying the reperfusion syndrome may involve cellular calcium overload, over-production of oxygen-derived free radicals, acidosis and/or development of an inflammatory reaction. Numerous pharmacological studies have been conducted over several years designed to limit such reperfusion injury and, consequently, prevent stunning and/or reperfusion-induced arrhythmias. A number of experimental studies in this field have demonstrated that trimetazidine exerts direct anti-ischaemic effects, limiting calcium accumulation and acidosis, inflammation and oxygen-derived free radical production following reperfusion. This agent therefore appears to be particularly promising clinically in the treatment of reperfusion lesions, for example in combination with thrombolysis during the acute phase of myocardial infarction.
J de Leiris; F Boucher
Related Documents :
2970839 - Coronary thrombolysis with and without nifedipine in pigs.
16953089 - Effects of olprinone on myocardial ischemia-reperfusion injury in dogs.
7690089 - Coronary venous retroinfusion of felodipine reduces myocardial necrosis after coronary ...
7860929 - A chimeric igg4 monoclonal antibody directed against cd18 reduces infarct size in a pri...
7799519 - Effects of ns-2, a new class 1 antiarrhythmic agent, and afd-19, its active metabolite,...
1884619 - Cardiac function after hepatic ischemia-anoxia and reperfusion injury: a new experiment...
22268109 - Biphasic modulation of the mitochondrial electron transport chain in myocardial ischemi...
7480969 - Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
3446369 - Quantitative and temporal relation between the release of myoglobin and creatine kinase...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology     Volume:  13     ISSN:  0870-2551     ISO Abbreviation:  Rev Port Cardiol     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-02-16     Completed Date:  1995-02-16     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8710716     Medline TA:  Rev Port Cardiol     Country:  PORTUGAL    
Other Details:
Languages:  eng     Pagination:  661-7     Citation Subset:  IM    
Groupe de Recherche sur la Physiopathologic Cellulaire Cardiaque Université Joseph Fourier, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acidosis / etiology
Calcium / metabolism
Energy Metabolism
Free Radicals
Myocardial Ischemia / complications,  drug therapy*,  physiopathology
Myocardial Reperfusion Injury / etiology,  physiopathology,  prevention & control*
Myocarditis / etiology
Reactive Oxygen Species
Trimetazidine / therapeutic use*
Reg. No./Substance:
0/Free Radicals; 0/Reactive Oxygen Species; 5011-34-7/Trimetazidine; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myocardial damage during ischaemia and reperfusion.
Next Document:  Hemodynamic effects of propafenone in dogs anesthesized with halothane or isoflurane